|
26 Jun 2023 |
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
|
|
26 Jun 2023 |
Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
|
|
26 Jun 2023 |
CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
|
|
26 Jun 2023 |
First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
|
|
25 Jun 2023 |
Hemab Therapeutics Presents New Preclinical Research Demonstrating Effects of Its Bispecific Antibody HMB-001 in Factor VII Deficiency
|
|
25 Jun 2023 |
Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
|
|
24 Jun 2023 |
Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review
|
|
23 Jun 2023 |
Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People
|
|
23 Jun 2023 |
Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome
|
|
23 Jun 2023 |
Palleon Pharmaceuticals Announces First Patient Dosed with E-602 in Combination with Cemiplimab in GLIMMER-01 Phase 1/2 Clinical Trial
|
|
23 Jun 2023 |
HiFiBiO Therapeutics Announces First Patient Dosed with HFB200301 in Combination with tislelizumab in Patients with DIS® Selected Advanced Solid Tumors
|
|
22 Jun 2023 |
Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics
|
|
22 Jun 2023 |
Alchemab Therapeutics unveils Alzheimer's candidate ATLX-1088 targeting CD33 at the Antibody Industrial Symposium
|
|
22 Jun 2023 |
Memo Therapeutics AG Starts U.S. Pivotal Phase II/III Clinical Trial with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients
|
|
21 Jun 2023 |
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
|
|
21 Jun 2023 |
Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors
|
|
21 Jun 2023 |
Longbio Pharma Presented Positive Topline Phase 1 Results for LP-003 at ERS2023
|
|
21 Jun 2023 |
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
|
|
21 Jun 2023 |
Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
|
|
21 Jun 2023 |
Phase 3 Trial of ADCETRIS® (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma
|
|
18 Jun 2023 |
Ranibizumab (Lucentis) Biosimilars Pipeline Review
|
|
18 Jun 2023 |
IASO Bio Receives FDA Approval of IND Application for IASO-782 for Treatment of Autoimmune Disease
|
|
16 Jun 2023 |
First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention
|
|
16 Jun 2023 |
Coherus to Acquire Surface Oncology
|
|
16 Jun 2023 |
TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody
|
